Roche signs up Dicerna in a $200M-plus cash alliance to help develop a hep B cocktail, capping the biotech's big year
Over the past year we’ve seen a string of collaborations between Big Pharma players and some up-and-coming biotechs over next-gen approaches to hepatitis B. Now one of the biggest in the top 10 has allied itself with Dicerna on an RNAi approach to help curing the disease. And they’re fronting the pact with $200 million in cold, hard cash — a standout in this field.
The Big Pharma player in this deal is Roche — the Basel side on pRED — which has pitched in with an RNAi company that has had to endure quite a long chill before it settled up with Alnylam on a simmering dispute and lined up a list of major alliances to establish its place in the RNAi world.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 64,900+ biopharma pros reading Endpoints daily — and it's free.